endometrial hyperplasia
Conditions
Interventions
trial group:Drospirenone ethinyl estradiol tablet (II) and Metformin
control group:Dydrogesterone and Metformin
Sponsors
Shanghai General Hospital
Eligibility
Sex/Gender
Female
Age
20 Years to 45 Years
Inclusion criteria
Inclusion criteria: (1)Age =45 years old (2)Endometrial sampling under hysteroscope for pathological diagnosis of endometrial hyperplasia (EH); Note: The patient underwent hysteroscopic surgery due to abnormal uterine bleeding (AUB), previous history of EH, and thickened endometrium on ultrasound; (3)Sign informed consent (4)The patient agrees to the treatment and has good compliance and can be followed up and re-intimal pathology examination;
Exclusion criteria
Exclusion criteria: (1)Diagnosis of endometrial atypical hyperplasia or endometrioid adenocarcinoma by pathological biopsy at the beginning or after treatment, and consultation with a pathologist; (2)Combined with serious medical diseases: cerebrovascular disease, coronary heart disease, diabetes, high blood pressure, obesity, severe fatty liver, severe hyperlipidemia, renal impairment, adrenal hypofunction; (3)Those with an increased risk of arterial or venous thromboembolism, stroke, and myocardial infarction; including women who are known to have the following conditions: 1)Smoking; 2)Deep vein thrombosis or pulmonary embolism present or in the past; 3)Thrombotic valvular heart disease or thrombotic heart rhythm disease (such as subacute bacterial endocarditis with valvular disease or atrial fibrillation); 4)Inherited or acquired hypercoagulable disease; 5)Headache with focal neurological symptoms; or migraine with or without aura; (4)Undiagnosed abnormal uterine bleeding; (5)Current or past breast cancer or other estrogen or progesterone sensitive cancers, combined with other types of endometrial cancer or other malignant tumors of the reproductive system; (6)There may be multiple cancers and repeated cancer tendencies (breast cancer, ovarian cancer), Lynch syndrome, and Cowden syndrome in the family genetic history; (7)Liver benign or malignant tumors or liver diseases including hepatitis; (8)Pregnancy; (9)Allergic to the active ingredients of this product or any of its excipients;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| complete remission; | — |
Secondary
| Measure | Time frame |
|---|---|
| abnormal uterine bleeding;clinical pregnancy rate;sex hormones;Tumor index;Metabolic index;Immunohistochemistry;Effect; | — |
Countries
China
Contacts
Public ContactSufang Wu
Shanghai General Hospital
Outcome results
None listed